481 related articles for article (PubMed ID: 26197187)
1. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
[TBL] [Abstract][Full Text] [Related]
2. Cohort study of pioglitazone and cancer incidence in patients with diabetes.
Ferrara A; Lewis JD; Quesenberry CP; Peng T; Strom BL; Van Den Eeden SK; Ehrlich SF; Habel LA
Diabetes Care; 2011 Apr; 34(4):923-9. PubMed ID: 21447664
[TBL] [Abstract][Full Text] [Related]
3. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
[TBL] [Abstract][Full Text] [Related]
5. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
6. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
[TBL] [Abstract][Full Text] [Related]
7. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
Lewis JD; Ferrara A; Peng T; Hedderson M; Bilker WB; Quesenberry CP; Vaughn DJ; Nessel L; Selby J; Strom BL
Diabetes Care; 2011 Apr; 34(4):916-22. PubMed ID: 21447663
[TBL] [Abstract][Full Text] [Related]
8. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone Use and Risk of Bladder Cancer.
Davies BJ
JAMA; 2015 Dec; 314(23):2568. PubMed ID: 26670977
[No Abstract] [Full Text] [Related]
10. Pioglitazone Use and Risk of Bladder Cancer.
Singh S; Suchard MA
JAMA; 2015 Dec; 314(23):2567-8. PubMed ID: 26670976
[No Abstract] [Full Text] [Related]
11. Pioglitazone Use and Risk of Bladder Cancer--Reply.
Ferrara A; Lewis JD; Habel LA
JAMA; 2015 Dec; 314(23):2568-9. PubMed ID: 26670978
[No Abstract] [Full Text] [Related]
12. No strong association is found between pioglitazone and bladder cancer.
Wise J
BMJ; 2015 Jul; 351():h3934. PubMed ID: 26202496
[No Abstract] [Full Text] [Related]
13. Pioglitazone use and risk of bladder cancer: population based cohort study.
Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone use and the risk of bladder cancer.
Kuo HW; Tiao MM; Ho SC; Yang CY
Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
[TBL] [Abstract][Full Text] [Related]
16. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone--when is a prescription drug safe?
Loke YK; Mattishent K
Nat Rev Urol; 2015 Dec; 12(12):655-6. PubMed ID: 26416647
[No Abstract] [Full Text] [Related]
18. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
